Global Restless Legs Syndrome Market Research Report 2022

Market Analysis and Insights: Global Restless Legs Syndrome Market
Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
The global Restless Legs Syndrome market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Restless Legs Syndrome market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Restless Legs Syndrome market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Restless Legs Syndrome market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Restless Legs Syndrome market.
Global Restless Legs Syndrome Scope and Market Size
Restless Legs Syndrome market is segmented by players, region (country), by Type and by End User. Players, stakeholders, and other participants in the global Restless Legs Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by End User for the period 2017-2028.
Segment by Type
Pharmacological Therapy
Non-Pharmacological Therapy
Segment by End User
Below 35 Years Old
From 35 to 50 Years Old
Above 50 Years Old
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Boehringer Ingelheim GmbH
UCB SA
Astellas
Arbor Pharmaceuticals
GlaxoSmithKline plc.
Ligand Pharmaceuticals Incorporated
axxonis Pharma AG
Kyowa Hakko Kirin Co.
Jazz Pharmaceuticals, Inc.
Omeros Corporation
Manhattan Pharmaceuticals